Diagnosing myelodysplastic/myeloproliferative neoplasms: Laboratory testing strategies to exclude other disorders

International Journal of Laboratory Hematology

Volumn 32, Issue 6 PART 2, 2010, Pages 559-571

  Hall, J ^a   Foucar, K ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

chronic; myelodysplastic; Myeloid; myeloproliferative; neoplasm

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JANUS KINASE 2; MYELOPEROXIDASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ATYPICAL CHRONIC MYELOID LEUKEMIA; BLOOD CELL COUNT; BONE MARROW; BONE MARROW BIOPSY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; CLINICAL FEATURE; CYTOCHEMISTRY; DIFFERENTIAL DIAGNOSIS; DYSERYTHROPOIESIS; DYSPLASIA; EOSINOPHIL; ERYTHROPOIESIS; FLOW CYTOMETRY; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MEGAKARYOPOIESIS; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MYELOFIBROSIS; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; GRANULOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MEGAKARYOCYTES; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-BCR; THROMBOCYTOSIS;

EID: 78349258526     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01251.x     Document Type: Review

References (58)

1. Arber D.A., Brunning R.D., Le Beau M.M., Falini B., Vardiman J.W., Porwit A., Thiele J., &, Bloomfield C.D., (2008) Acute myeloid leukemia with recurrent genetic abnormalities. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds, S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, &, J.W. Vardiman,), 4th edn, IARC Press, Lyon, France.
2. Atallah E., Nussenzveig R., Yin C.C., Bueso-Ramos C., Tam C., Manshouri T., Pierce S., Kantarjian H., &, Verstovsek S., (2008) Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia, 22, 1295 - 1298.
3. Baxter E.J., Hochhaus A., Bolufer P., Reiter A., Fernandez J.M., Senent L., Cervera J., Moscardo F., Sanz M.A., &, Cross N.C., (2002) The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 11, 1391 - 1397.
4. Beran M., Wen S., Shen Y., Onida F., Jelinek J., Cortes J., Giles F., &, Kantarjian H., (2007) Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leukaemia & Lymphoma, 48, 1150 - 1160.
5. Breccia M., Biondo F., Latagliata R., Carmosino I., Mandelli F., &, Alimena G., (2006) Identification of risk factors in atypical chronic myeloid leukemia. Haematologica, 91, 1566 - 1568.
6. Carulli G., Fabiani O., &, Azzara A., (1997) The syndrome of abnormal chromatin clumping in leukocytes. Haematologica, 82, 635 - 636.
7. Chen Y.C., Chou J.M., Ketterling R.P., Letendre L., &, Li C.Y., (2003) Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. American Journal of Clinical Pathology, 120, 874 - 881.
8. De Vries A.C., Zwaan C.M., &, Van Den Heuvel-Eibrink M.M., (2010) Molecular basis of juvenile myelomonocytic leukemia. Haematologica, 95, 179 - 182.
9. Drechsler M., Hildebrandt B., Kundgen A., Germing U., &, Royer-Pokora B., (2007) Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Annals of Hematology, 86, 353 - 354.
10. Dunphy C.H., Orton S.O., &, Mantell J., (2004) Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and of flow cytometric immunophenotyping to the evaluation of absolute monocytoses. American Journal of Clinical Pathology, 122, 865 - 874.
11. Dunphy C.H., Polski J.M., Evans H.L., &, Gardner L.J., (2001) Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117, and myeloperoxidase. Archives of Pathology and Laboratory Medicine, 125, 1063 - 1069.
12. Dunphy C.H., O'malley D.P., Perkins S.L., &, Chang C.C., (2007) Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias. Applied Immunohistochemistry & Molecular Morphology, 15, 154 - 159.
13. Felman P., Bryon P.A., Gentilhomme O., Ffrench M., Charrin C., Espinouse D., &, Viala J.J., (1988) The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features? British Journal Haematology, 70, 49 - 54.
14. Fend F., Horn T., Koch I., Vela T., &, Orazi A., (2008) Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leukemia Research, 32, 1931 - 1935.
15. Foucar K., (2009) Myelodysplastic/myeloproliferative neoplasms. American Journal of Clinical Pathology, 132, 281 - 289.
16. Garcia J.L., Font De Mora J., Hernandez J.M., Queizan J.A., Gutierrez N.C., &, San Miguel J.F., (2003) Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood, 102, 2699 - 2700.
17. Gattermann N., Billiet J., Kronenwett R., Zipperer E., Germing U., Nollet F., Criel A., &, Selleslag D., (2007) High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count>600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood, 109, 1334 - 1335.
18. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., Carbuccia N., Lagarde A., Prebet T., Nezri M., Sainty D., Olschwang S., Xerri L., Chaffanet M., Mozziconacci M.J., Vey N., &, Birnbaum D., (2009) Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal Haematology, 145, 788 - 800.
19. Germing U., Strupp C., Knipp S., Kuendgen A., Giagounidis A., Hildebrandt B., Aul C., Haas R., Gattermann N., &, Bennett J.M., (2007) Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica, 92, 974 - 977.
20. Grand F.H., Hidalgo-Curtis C.E., Ernst T., Zoi K., Zoi C., Mcguire C., Kreil S., Jones A., Score J., Metzgeroth G., Oscier D., Hall A., Brandts C., Serve H., Reiter A., Chase A.J., &, Cross N.C., (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood, 113, 6182 - 6192.
21. Hasserjian R.P., Le Beau M.M., List A.F., Bennett J.M., &, Thiele J., 2008 Myelodysplastic syndrome with isolated del(5q). In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (eds, S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, &, J.W. Vardiman,), 4th edn. IARC Press, Lyon, France.
22. Hernandez J.M., Del Canizo M.C., Cuneo A., Garcia J.L., Gutierrez M., Gonzalez N.C., Castoldi G., &, San Miguel J.F., (2000) Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Annals of Oncology, 11, 441 - 444.
23. Horny H.P., Sotlar K., Sperr W.R., &, Valent P., (2004) Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. Journal of Clinical Pathology, 57, 604 - 608.
24. Ingram W., Lea N.C., Cervera J., Germing U., Fenaux P., Cassinat B., Kiladjian J.J., Varkonyi J., Antunovic P., Westwood N.B., Arno M.J., Mohamedali A., Gaken J., Kontou T., Czepulkowski B.H., Twine N.A., Tamaska J., Csomer J., Benedek S., Gattermann N., Zipperer E., Giagounidis A., Garcia-Casado Z., Sanz G., &, Mufti G.J., (2006) The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia, 20, 1319 - 1321.
25. Invernizzi R., Custodi P., Fazio De P., Bergamaschi G., Fenoglio C., Ricevuti G., Rosti V., Zambelli L.M., &, Ascari E., (1990) The syndrome of abnormal chromatin clumping in leucocytes: clinical and biological study of a case. Haematologica, 75, 532 - 536.
26. Jankowska A.M., Szpurka H., Tiu R.V., Makishima H., Afable M., Huh J., O'keefe C.L., Ganetzky R., Mcdevitt M.A., &, Maciejewski J.P., (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood, 113, 6403 - 6410.
27. Jegalian A.G., Facchetti F., &, Jaffe E.S., (2009) Plasmacytoid dendritic cells: physiologic roles and pathologic states. Advances in Anatomic Pathology, 16, 392 - 404.
28. Kremer M., Horn T., Dechow T., Tzankov A., Quintanilla-Martinez L., &, Fend F., (2006) The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. Leukemia, 20, 1315 - 1316.
29. Kuo M.C., Liang D.C., Huang C.F., Shih Y.S., Wu J.H., Lin T.L., &, Shih L.Y., (2009) RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia, 23, 1426 - 1431.
30. Kussick S.J., Fromm J.R., Rossini A., Li Y., Chang A., Norwood T.H., &, Wood B.L., (2005) Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. American Journal of Clinical Pathology, 124, 170 - 181.
31. Lacronique-Gazaille C., Chaury M.P., Le Guyader A., Faucher J.L., Bordessoule D., &, Feuillard J., (2007) A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica, 92, 859 - 860.
32. Malcovati L., Della Porta M.G., Pietra D., Boveri E., Pellagatti A., Galli A., Travaglino E., Brisci A., Rumi E., Passamonti F., Invernizzi R., Cremonesi L., Boultwood J., Wainscoat J.S., Hellstrom-Lindberg E., &, Cazzola M., (2009) Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood, 114, 3538 - 3545.
33. Ngo N.T., Lampert I.A., &, Naresh K.N., (2008) Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia. British Journal Haematology, 141, 771 - 781.
34. Olsen R.J., Dunphy C.H., O'malley D.P., Rice L., Ewton A.A., &, Chang C.C., (2008) The implication of identifying JAK2 (V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis. Journal of Hematopathology, 1, 111 - 117.
35. Onida F., Ball G., Kantarjian H.M., Smith T.L., Glassman A., Albitar M., Scappini B., Rios M.B., Keating M.J., &, Beran M., (2002a) Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer, 95, 1673 - 1684.
36. Onida F., Kantarjian H.M., Smith T.L., Ball G., Keating M.J., Estey E.H., Glassman A.B., Albitar M., Kwari M.I., &, Beran M., (2002b) Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 99, 840 - 849.
37. Orazi A., &, Germing U., (2008) The myelodysplastic/ myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia, 22, 1308 - 1319.
38. Orazi A., Chiu R., O'malley D.P., Czader M., Allen S.L., An C., &, Vance G.H., (2006) Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Modern Pathology, 19, 1536 - 1545.
39. Orazi A., Bennett J.M., Germing U., Brunning R.D., Bain B.J., &, Thiele J., (2008) Chronic myelomonocytic leukemia. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds, S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, &, J.W. Vardiman,), 4th edn. IARC Press, Lyon, France.
40. Schmitt-Graeff A.H., Teo S.S., Olschewski M., Schaub F., Haxelmans S., Kirn A., Reinecke P., Germing U., &, Skoda R.C., (2008) JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica, 93, 34 - 40.
41. Schnittger S., Bacher U., Haferlach C., Dengler R., Krober A., Kern W., &, Haferlach T., (2008) Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia, 22, 453 - 455.
42. Sokol L., Caceres G., Rocha K., Stockero K.J., Dewald D.W., &, List A.F., (2010) JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leukemia Research 34, 821 - 823.
43. Sotlar K., Colak S., Bache A., Berezowska S., Krokowski M., Bultmann B., Valent P., &, Horny H.P., (2010) Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). Journal of Pathology, 220, 586 - 595.
44. Szpurka H., Tiu R., Murugesan G., Aboudola S., Hsi E.D., Theil K.S., Sekeres M.A., &, Maciejewski J.P., (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, 2173 - 2181.
45. Thiele J., (2009) Philadelphia chromosome-negative chronic myeloproliferative disease. American Journal of Clinical Pathology, 132, 261 - 280.
46. Vardiman J.W., Bennett J.M., Bain B.J., Baumann I., Thiele J., &, Orazi A., (2008a) Myelodysplastic/myeloproliferative neoplasm, unclassifiable. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, (eds, S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, &, J.W. Vardiman,), 4th edn. IARC Press, Lyon, France.
47. Vardiman J.W., Bennett J.M., Bain B.J., Brunning R.D., &, Thiele J., (2008b) Atypical chronic myeloid leukemia, BCR-ABL1 negative. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds, S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, &, J.W. Vardiman, (eds.), 4th edn. IARC Press, Lyon, France.
48. Vardiman J.W., Brunning R.D., Arber D.A., Beau Le M.M., Porwit A., Tefferi A., Bloomfield C.D., &, Thiele J., (2008c) Introduction and overview of the classification of the myeloid neoplasms. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds, S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, &, J.W. Vardiman,. 4th edn. IARC Press, Lyon, France.
49. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellstrom-Lindberg E., Tefferi A., &, Bloomfield C.D., (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937 - 951.
50. Verma D., Kantarjian H.M., Jones D., Luthra R., Borthakur G., Verstovsek S., Rios M.B., &, Cortes J., (2009) Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood, 114, 2232 - 2235.
51. Wang S.A., Galili N., Cerny J., Sechman E., Chen S.S., Loew J., Liu Q., Fadare O., Hasserjian R., Jones D., Qawi H., Woda B., &, Raza A., (2006a) Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. American Journal of Clinical Pathology, 126, 789 - 797.
52. Wang S.A., Hasserjian R.P., Loew J.M., Sechman E.V., Jones D., Hao S., Liu Q., Zhao W., Mehdi M., Galili N., Woda B., &, Raza A., (2006b) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia, 20, 1641 - 1644.
53. Wardrop D., &, Steensma D.P., (2009) Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? British Journal Haematology, 144, 809 - 817.
54. Washington L.T., Doherty D., Glassman A., Martins J., Ibrahim S., &, Lai R., (2002) Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum. Leukaemia & Lymphoma, 43, 761 - 765.
55. Xu Y., Dolan M.M., &, Nguyen P.L., (2003) Diagnostic significance of detecting dysgranulopoiesis in chronic myeloid leukemia. American Journal of Clinical Pathology, 120, 778 - 784.
56. Xu Y., Mckenna R.W., Karandikar N.J., Pildain A.J., &, Kroft S.H., (2005) Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. American Journal of Clinical Pathology, 124, 799 - 806.
57. Xubo G., Xingguo L., Xianguo W., Rongzhen X., Xibin X., Lin W., Lei Z., Xiaohong Z., Genbo X., &, Xiaoying Z., (2009) The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. European Journal of Haematology, 83, 292 - 301.
58. Yang D.T., Greenwood J.H., Hartung L., Hill S., Perkins S.L., &, Bahler D.W., (2005) Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations. American Journal of Clinical Pathology, 124, 930 - 936.